Free Trial
NASDAQ:CALA

Calithera Biosciences (CALA) Stock Price, News & Analysis

Calithera Biosciences logo
$0.0006 0.00 (0.00%)
As of 05/23/2025

About Calithera Biosciences Stock (NASDAQ:CALA)

Key Stats

Today's Range
$0.0006
$0.0006
50-Day Range
N/A
52-Week Range
$0.00
$0.12
Volume
67 shs
Average Volume
18,694 shs
Market Capitalization
$2,922.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Stock News Headlines

Calithera Biosciences Inc (CALA)
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Arcus Biosciences Inc (RCUS)
Christina Cala
CALA - Calithera Biosciences, Inc.
See More Headlines

CALA Stock Analysis - Frequently Asked Questions

Calithera Biosciences' stock was trading at $0.0001 at the start of the year. Since then, CALA stock has increased by 500.0% and is now trading at $0.0006.
View the best growth stocks for 2025 here
.

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter.

Calithera Biosciences's stock reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR).

Company Calendar

Last Earnings
11/08/2021
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
60
Year Founded
2010

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
4,550,000
Market Cap
$2,922.00
Optionable
Not Optionable
Beta
-2.38

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CALA) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners